

**International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis (INTERTB)  
St. George's, University of London  
Friday November 17<sup>th</sup>, 2017, Hunter Wing Room H2.7  
AGENDA**

**08.30 – 09.00 REGISTRATION**

**First morning session –Chair: Dr. Rajko Reljic ©**

09.00 – 09.10	Welcome to the Symposium	<b>Rajko Reljic ©</b>
09.10 – 09.25	The Story So Far	Amina Jindani©
09.25 – 09.45	The ANRS RIFAVIRENZ Trial	Anne-Marie Taburet©
09.45 – 10.05	The EDCTP RAFA Trial	Corinne Merle©
10.05 – 10.25	The TBTC STUDY 31	Payam Nahid ©
10.25 – 10.45	The ALLIANCE Phase III Trials	Carl Mendel©
10.45 – 11.00	The INTERTB RIFASHORT Trial	Claire Robb©

**11.00 – 11.30 COFFEE BREAK**

**Second morning session - Guest Chair: Dr. Rada Savic ©**

11.30 – 11.45	The INTERTB RIFASHORT Persister Study	Mike Barer ©
11.45 – 12.00	Higher dosages of rifampicin: how high must we go	Martin Boeree©
12.00 – 12.20	More lessons from the PanACEA MAMS Study	Norbert Heinrich©
12.20 – 12.40	The TBTC ASTEROID Trial for LTBI	Tim Sterling©
12.40 – 13.00	The MRC STREAM Trial- Preliminary results	Sarah Meredith/Andrew Nunn©
13.00 – 13.15	<b>PANEL DISCUSSION: Bonnet, Merle, Nahid, Robb, Barer, Heinrich, Boeree, Phillips, Sterling, Meredith, Nunn, Mendel.</b>	

**13.15 – 14.00 LUNCH**

**Afternoon session - Chair: Professor Tom Harrison©**

14.00 – 14.20	Treatment stratification in the design of future clinical trials	Patrick Phillips©
14.20 – 14.40	Concurrent TB and Diabetes: Bi-directional screening and Public Health Implications	Julia Critchley©
14.40 – 15.00	The INTERTB RIFAQUIN Whole Genome Study	Adam Witney©
15.00 – 15.20	The role of chest radiographs in RCTs of tuberculosis	Conor Tweed/Andrew Nunn ©
15.20 – 15.40	TB persistence is futile, time to end them all	Yanmin Hu©
15.40 – 16.00	Towards treatment individualization and cure for all.	Rada Savic©
16.00 – 16.20	PreDiCT-TB : Learning from Preclinical data	Gerry Davies ©
16.20 – 16.40	Critical Role of Data Collaboration for Advancing Novel TB Treatments	Debra Hanna©
16.40 – 17.00	The Global TB Drug Pipeline - New Chemical Entities	Barbara Laughon©
17.00 – 17.20	The economics of new TB drugs and regimens.	Gabriela Gomez
17.20 – 17.40	Quo vadimus	Carl Mendel©
17.40 – 17.55	<b>DISCUSSION: Critchley, Nunn, Witney, Laughon, Savic, Davies, Hanna, Hu, Tweed, Mendel Gomez.</b>	
17.55 – 18.00	Close of Symposium	Tom Harrison ©

**18.00 RECEPTION**